Clinical DataBeam Therapeutics has not yet presented any clinical data from any of its programs, which is essential to justify its current valuation.
Market CompetitionThe company's lead indication for sickle cell disease is in a crowded market, with competitors already ahead in terms of clinical data.
Valuation ConcernsBeam Therapeutics is trading at a high implied enterprise value compared to peers without clinical data, raising concerns about overvaluation.